<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303364</url>
  </required_header>
  <id_info>
    <org_study_id>C19-10</org_study_id>
    <nct_id>NCT04303364</nct_id>
  </id_info>
  <brief_title>CARdiomyopathy in Type 2 DIAbetes Mellitus</brief_title>
  <acronym>CARDIATEAM</acronym>
  <official_title>CARdiomyopathy in Type 2 DIAbetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the CARDIATEAM clinical study is to assess the uniqueness of diabetic&#xD;
      cardiomyopathy (DCM) relative to other forms of cardiomyopathy using unsupervised clustering&#xD;
      approaches based on deep phenotyping (clinical, imaging and biological) information.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CARDIATEAM study will address the uniqueness of DCM, and its progression towards heart&#xD;
      failure (HF) with preserved ejection fraction (HFpEF) by recruiting a prospective CARDIATEAM&#xD;
      cohort (n=1600 individuals) from existing cohorts using a defined set of selection criteria&#xD;
      and will include type2-Diabetes mellitus (T2DM)and non-diabetic patients with a large&#xD;
      spectrum of demographic, metabolic and cardiac clinical data. This will yield a wide range of&#xD;
      T2DM - related phenotypes including common confounders such as BMI, smoking, age and blood&#xD;
      pressure.&#xD;
&#xD;
      To clarify the phenotype of DCM and to differentiate it from the other forms of HF such as&#xD;
      HFpEF or HCM, CARDIATEAM will perform unbiased clustering analysis from an in-depth&#xD;
      phenotyping of these patients' populations&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy</measure>
    <time_frame>3 years</time_frame>
    <description>Use of unsupervised clustering approaches based on deep phenotyping (clinical, imaging and biological) information</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify the best clinical, biological, imaging and multi-OMICs predictors belonging to each identified cluster</measure>
    <time_frame>4 years</time_frame>
    <description>Specific focus on cluster(s) relating to a putative diabetic cardiomyopathy comparatively to other clusters [diagnostic perspective]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess prospective health outcomes (i.e. overall mortality, cardiovascular events and cardiac function) in the diabetic cardiomyopathy cluster identified</measure>
    <time_frame>5 years</time_frame>
    <description>Compare them to those from the other clusters and pre-defined patient groups [prognostic perspective]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the pathophysiological and potentially causal pathways characterizing diabetic cardiomyopathy</measure>
    <time_frame>5 years</time_frame>
    <description>Better understand the underlying mechanisms responsible for establishment and progression of disease, based on OMICs data and causal inference modeling</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Cardiomyopathy, Diabetic</condition>
  <arm_group>
    <arm_group_label>Subjects without T2DM and without HF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without T2DM and with HFpEF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with T2DM and without HFpEF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with T2DM and HFpEF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without T2DM and with hypertrophic cardiomyopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with T2DM and with hypertrophic cardiomyopathy</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma EDTA, Serum, Paxgene RNA, Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Since CARDIATEAM aims to assess the uniqueness of DCM, it will include a group of&#xD;
        non-diabetic non-HFpEF individuals with diversified characteristics relating to obesity,&#xD;
        glucose intolerance and hypertension. Consequently, CARDIATEAM cohort will recruit both&#xD;
        non-diabetic and diabetic patients with a large spectrum of demographic, metabolic and&#xD;
        cardiac (heart failure vs. no heart failure) clinical data.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal LVEF AND absence of akinetic segment assessed by echocardiography&#xD;
             (i.e.LVEF≥50%)&#xD;
&#xD;
          -  Patients diagnosed according to the specific diagnostic criteria of each disease. For&#xD;
             each group, the diagnosis will be based on current accepted criteria:&#xD;
&#xD;
               -  HFpEF: LVEF≥50% AND presence/or history of symptoms or signs of HF AND&#xD;
                  significant diastolic dysfunction OR NT-proBNP &gt;125 pg/Ml&#xD;
&#xD;
               -  NoHFpEF:LVEF≥50% AND absenceofsymptoms or signs of HF&#xD;
&#xD;
               -  T2DM:HbA1c≥6.5% (≥48mmol/L)AND Fasting Plasma Glucose≥7.0mmol/L (≥126 mg/dL) or&#xD;
                  anti-diabetic treatment&#xD;
&#xD;
               -  Normoglycemia defined as HbA1C &lt;5.7% (39mmol/L) AND Fasting Plasma Glucose &lt;5.6&#xD;
                  mmol/L (100mg/dL)&#xD;
&#xD;
               -  HCM: patients with non-obstructive HCM of sarcomeric cause (proven with common&#xD;
                  genetic cause) and with LV wall thickness ≥ 15 mm in one or more myocardial&#xD;
                  segments in the absence of abnormal afterload conditions.&#xD;
&#xD;
          -  Suitable echocardiographic window&#xD;
&#xD;
          -  Absence of history of coronary artery disease including history of myocardial&#xD;
             ischaemia, myocardial infarction or percutaneous coronary intervention&#xD;
&#xD;
          -  Absence of significant coronary artery disease (CAD) defined as&#xD;
&#xD;
               -  a negative stress test: stress echocardiography, myocardial perfusion&#xD;
                  scintigraphy or cardiac stress MRI performed within the 18 months before&#xD;
                  inclusion OR&#xD;
&#xD;
               -  the absence of coronary stenosis ≥50% on a cardiac computed tomography (CT) or&#xD;
                  coronary angiography performed within the 18 months before inclusion&#xD;
&#xD;
          -  Patient covered by a health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Diabetes mellitus other than type 2 (type 1, LADA, MODY, NODAT, etc.)&#xD;
&#xD;
          -  Suboptimal echocardiographic window&#xD;
&#xD;
          -  Significant valvular heart disease defined as severe aortic regurgitation or severe&#xD;
             primary mitral regurgitation or aortic stenosis with a peak transvalvular velocity&#xD;
             ≥3m/s or mitral stenosis with a mitral valve area &lt; 1.5cm2&#xD;
&#xD;
          -  Chronic atrial fibrillation or any significant arrhythmia at inclusion&#xD;
&#xD;
          -  Renal insufficiency defined as eGFR&lt;30 mL/min/1.73m2&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Obstructive hypertrophic cardiomyopathy (definition: maximal gradient at rest &lt;30mmHg)&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy due to a non-sarcomeric etiology&#xD;
&#xD;
          -  Life threatening comorbidities (i.e. cancer, end-stage heart failure, severe lung&#xD;
             disease, cirrhosis)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactating mother&#xD;
&#xD;
          -  Any condition which in the Investigator's opinion makes it undesirable for the subject&#xD;
             to participate in the study or which would jeopardize compliance with the protocol&#xD;
&#xD;
          -  Inability to understand the local language&#xD;
&#xD;
          -  Individuals deprived of liberty&#xD;
&#xD;
          -  Protected persons (under guardianship or curatorship)&#xD;
&#xD;
          -  Contra-indication to CMR&#xD;
&#xD;
          -  Known hypersensitivity to gadolinium based product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geneviève DERUMEAUX, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geneviève DERUMEAUX, MD, PhD</last_name>
    <phone>+33 (0)603613517</phone>
    <email>genevieve.derumeaux@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne PIZARD, PhD</last_name>
    <phone>+33(0)149814398</phone>
    <email>anne.pizard@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Outpatient Department at Hôpital Henri Mondor.</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève Derumeaux, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrille Bergerot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>department of diabetology and nutrition, APHM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Dutour, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetology departement, Lariboisière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Gautier, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetology department, Cochin Institute</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Boitard, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Étienne Larger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikolaus Marx, Univ.-Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Meder, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. Louis Handoko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG), Cardiology/Cardio Research</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rudolf de Boer, Prof dr.</last_name>
    </contact>
    <investigator>
      <last_name>Victor Zwartkruis, drs</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch ziekenhuis Maastricht, Cardiology</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephane Heymans, Prof, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Vanessa van Empel, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht, Cardiology (DHL)</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Folkert Asselbergs, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Rodríguez Palomares, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Bermejo, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José L. Zamorano, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Dundee, Div of Molecular&amp;Clinical Medicine</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chim Lang, Prof, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type2 Diabetes Mellitus</keyword>
  <keyword>Heart Failure with preserved ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

